Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.

Cancer immunology, immunotherapy : CII - 1 Jun 2021

Del Re Marzia, Cucchiara Federico, Rofi Eleonora, Fontanelli Lorenzo, Petrini Iacopo, Gri Nicole, Pasquini Giulia, Rizzo Mimma, Gabelloni Michela, Belluomini Lorenzo, Crucitta Stefania, Ciampi Raffaele, Frassoldati Antonio, Neri Emanuele, Porta Camillo, Danesi Romano

Abstract excerpt

BACKGROUND: It is still unclear how to combine biomarkers to identify patients who will truly benefit from anti-PD-1 agents in NSCLC. This study investigates exosomal mRNA expression of PD-L1 and IFN-γ, PD-L1 polymorphisms, tumor mutational load (TML) in circulating cell-free DNA (cfDNA) and radiomic features as possible predictive markers of response to nivolumab and pembrolizumab in metastatic NSCLC patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Carcinoma, Non-Small-Cell Lung

Share to Cell-Free Nucleic Acids

Share to Nivolumab

Share to Survival Rate

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 33315149
DOI: 10.1007/s00262-020-02810-6
PMCID: PMC8139911

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.PMID 33315149Read ↗

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read ↗

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.Semantic proximity Read ↗

Longitudinal Whole-Exome Sequencing of Cell-Free DNA Reveals Molecular Evolution and Heterogeneous Clinical Outcomes in PD-L1 Stratified Advanced NSCLC Adenocarcinoma Patients Treated with Atezolizumab.Semantic proximity Read ↗

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with NivolumabSemantic proximity Read ↗

Towards a Survival Risk Prediction Model for Metastatic NSCLC Patients on Durvalumab Using Whole-Lung CT RadiomicsSemantic proximity Read ↗

Improving prediction of survival and progression in metastatic non-small cell lung cancer following immunotherapy through machine learning of circulating tumor DNA dynamicsSemantic proximity Read ↗

Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.Semantic proximity Read ↗

Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy.Semantic proximity Read ↗

Nivolumab after cyclophosphamide and doxorubicin induction chemotherapy in previously treated patients with EGFR or ALK wild type non-squamous cell non-small cell lung cancer with less than 10% of PD-L1 expressionSemantic proximity Read ↗

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLCSemantic proximity Read ↗

Aligning digital CD8+ scoring and targeted next‐generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early‐stage squamous cell lung carcinomaSemantic proximity Read ↗

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.